Global Community

Willamette Valley Vineyards looks cheap at first glance, but shrinking wine demand and rising costs are putting real pressure on the business. The company leans on investor-friendly “wine club” style funding and carries signs of cash strain, which could leave everyday shareholders last in line if things get worse.Read more

GTA Holdings Berhad is entering the ACE Market with an interesting combination of an established aviation MRO business, strong earnings growth and a clear expansion strategy. Unlike airlines or aircraft manufacturers, GTA operates behind the scenes, specialising in the maintenance, repair and overhaul (MRO) of helicopter and fixed-wing engines, while also supplying engines, modules, parts and aviation equipment.Read more

Lendlease (ASX: LLC) at $2.80 — Cheap Assets, But Is the Return Good Enough? I’ve rebuilt my Lendlease valuation following the FY26 result and stress-tested the original thesis.Read more

AS ONE just put up a record year, but it’s now choosing to spend more on new facilities and logistics that may hold back profits in the near term. The key question is whether these investments and rising demand for some everyday consumables can turn into stronger earnings in the years ahead.Read more

TheGapReport: Jack Henry & Associates, Inc. (JKHY) Q4 2026 (may 6 - aug 19) Jack Henry closed fiscal year 2026 on August 19 with a prepared remarks section that read less like a quarterly update than a victory lap — record core wins, record trifecta attach rates, record treasury signings, the largest bank client in company history.Read more

Jumia has spent years shrinking and simplifying its business just to stop bleeding money, and signs of a turnaround are starting to show as customers and orders pick up across key African markets. The big question now is whether it can truly break even as promised—or whether the same old challenges in the region pull it back into deeper losses.Read more

A tiny cancer biotech with a shaky cash situation just brought in a leadership team known for big drug deals, while its lead treatment shows early signs of helping the immune system attack hard-to-treat gut cancers. The big question is whether new funding and partners arrive in time to turn promising trial signals and helpful FDA momentum into a real path to approval.Read more

Brightstar is building a new gold processing plant in Western Australia and says it’s fully funded, with a clear path to become a bigger producer once construction and start-up go to plan. The bigger question is whether it can hit its timeline and costs while carrying expensive debt—and whether a second, much larger project can turn today’s exploration success into a real mine.Read more

A big overseas takeover turns Sudarshan into a global pigment leader, and the latest results suggest the worst of the integration pain may be fading as orders and cash flow improve. The key question now is whether the rebound is real demand or just a seasonal bounce—and one upcoming quarterly profit figure could settle it.Read more